New Cardiovascular Tests
MedLabs offers Inflammatory Biomarker Testing to assess risk for Cardiovascular DiseaseNearly 50% of all heart attacks and strokes occur in patients with ‘normal’ cholesterol levels, suggesting that routine cholesterol testing may be missing a lot of patients at risk1. Evidence now points to the benefit of measuring inflammation levels to identify ‘hidden’ risk that otherwise would have been missed with standard cholesterol testing.
Inflammation is a key contributor to heart attacks and strokes as it is involved in the formation of vulnerable plaque, or plaque that is at risk of rupturing and causing a heart attack or stroke. Inflammation levels can be easily be measured with simple blood or urine tests to assess a patient’s ‘spectrum’ of inflammatory risk – from lifestyle concerns and their risk of disease, to the presence of disease, and ultimately, their risk for a heart attack or stroke.
MedLabs is pleased to offer
The following advanced biomarker tests may help to identify risk for cardiovascular disease in addition to standard cholesterol testing.
Myeloperoxidase (MPO) is a marker that measures the body’s response to a damaged endothelium, or the lining of the arteries, that has become thin, cracked and ultimately unstable due to cholesterol accumulation and inflammation. The risk for a heart attack increases as MPO levels increase.
Lp-PLA2 (The PLAC® Test) is a marker that measures the active buildup of cholesterol inside the artery walls. The risk for a heart attack or stroke increase as your Lp-PLA2 levels increase.
Oxidized LDL (OxLDL) is a marker that measures the amount of LDL (or “bad”) cholesterol in your blood that has been damaged due to oxidation. Poor lifestyle habits may increase OxLDL levels and increase the risk for metabolic syndrome.
F2-Isoprostanes (F2-IsoPs) is a lifestyle marker that measures the amount of oxidation in the body that may damage the endothelium. Eating too much red meat, smoking or not exercising enough can increase F2-Isoprostanes levels and increase the risk for future heart disease.
1. Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207.
MedLabs began in 1951 with a vision to provide the highest quality and most advanced diagnostic testing services. Over the years we’ve learned that by providing the best diagnostic solutions to doctors, we help them provide the best care for their patients. We’re proud to be the diagnostics company that doctors can customize to their needs and to the needs of their patients. We are particularly proud of the fact that we are in our seventh decade of serving thousands of medical practices and their patients and we are experiencing the most dramatic changes and the fastest growth in the company’s history. This would not have been possible without the tireless and dedicated effort of the hundreds of MedLabs employees, who play a critical role in fulfilling our mission of providing the highest level of diagnostic testing and services to health care professionals and their patients each and every day.